BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Fundamental Analysis
BioMarin Pharmaceutical Inc. (BMRN) shows weak financial fundamentals with a PE ratio of 456.36, profit margin of 0.00%, and ROE of 0.46%. The company generates N/A in annual revenue with weak year-over-year growth of -1.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -64.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BMRN's fundamental strength across five key dimensions:
Efficiency Score
WeakBMRN struggles to generate sufficient returns from assets.
Valuation Score
WeakBMRN trades at a premium to fair value.
Growth Score
WeakBMRN faces weak or negative growth trends.
Financial Health Score
ExcellentBMRN maintains a strong and stable balance sheet.
Profitability Score
ModerateBMRN maintains healthy but balanced margins.
Key Financial Metrics
Is BMRN Expensive or Cheap?
P/E Ratio
BMRN trades at 456.36 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BMRN's PEG of 4.56 indicates potential overvaluation.
Price to Book
The market values BioMarin Pharmaceutical Inc. at 2.02 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.00 times EBITDA. This is generally considered low.
How Well Does BMRN Make Money?
Net Profit Margin
For every $100 in sales, BioMarin Pharmaceutical Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.46 in profit for every $100 of shareholder equity.
ROA
BioMarin Pharmaceutical Inc. generates $0.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $4.34 in free cash annually.
FCF Yield
BMRN converts 6.76% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
456.36
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.56
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.02
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.10
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.83
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.005
vs 25 benchmark
ROA
Return on assets percentage
0.004
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How BMRN Stacks Against Its Sector Peers
| Metric | BMRN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 456.36 | 29.43 | Worse (Expensive) |
| ROE | 0.46% | 800.00% | Weak |
| Net Margin | 0.00% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.10 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.83 | 4.64 | Strong Liquidity |
| ROA | 0.35% | -17936.00% (disorted) | Weak |
BMRN outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioMarin Pharmaceutical Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-97.04%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
Declining